Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma: A Multicenter Phase II Study

NCT07231250 is registered in ClinicalTrials.gov with Li Zhiming as lead sponsor.

NCT NCT07231250
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07231250 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma: A Multicenter Phase II Study
Lead sponsor
Li Zhiming
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 15, 2026
Completion date
September 15, 2028
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bispecific antibody, chemo-free therapy, dlbcl - diffuse large b cell lymphoma